antisense-based therapy

Isis Pharmaceuticals will test its experimental antisense drug in 24 children with spinal muscular atrophy at five U.S. centers

posted on January 2, 2012 - 6:00am
A 24-person, phase 1 trial to test the safety and tolerability of the experimental drug ISIS-SMNRx in children with spinal muscular atrophy (SMA) is now open at Columbia University Medical Center in New York, with additional sites expected to open in Boston, Philadelphia, Dallas and Salt Lake City.

New content is being added every day. Please check back again.